News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

S.Korea authorises Novavax COVID-19 vaccine, imports Pfizer pills

01/12/2022 | 01:07am EDT
FILE PHOTO: Vial and sryinge are seen in front of displayed Novavax logo in this illustration

SEOUL (Reuters) -South Korea is turning to additional pharmaceutical tools as it looks to pre-empt a surge of COVID-19 omicron infections, authorising the use of Novavax Inc's vaccine on Wednesday and preparing to distribute the first of Pfizer's antiviral pills.

At least 21,000 of Pfizer's antiviral pills, called Paxlovid, will arrive in South Korea on Thursday, with another 10,000 more expected to arrive by the end of the month, the health ministry said.

The pills, which were authorised for emergency use in December, will begin being used in treatments for more than 1,000 people per day starting on Friday, the ministry added

"By priority, oral treatment is planned to begin first for patients aged 65 or older, or patients with reduced immunity at home and residential treatment centres," a ministry spokesperson told a briefing.

Paxlovid was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer has said.

South Korea's food and drug safety ministry, meanwhile, announced it had authorised the Novavax vaccine, which joins the ranks of previously authorised vaccines made by AstraZeneca Inc, Moderna Inc, Pfizer, and Johnson & Johnson's Janssen.

South Korean vaccine developer SK Bioscience Co Ltd said it will produce the Novavax vaccine.

The two-dose, protein-based vaccine has secured authorisations from European Union regulators and the World Health Organization.

It has been authorised in India, Indonesia and the Philippines, where Novavax's partner, Serum Institute of India, will supply it.

Novavax is awaiting approval in Japan, where its vaccine would be manufactured and distributed by Takeda Pharmaceutical.

At least 84.2% of the country's 52 million population have been fully vaccinated, while 42.5%, have received booster shots, according to health officials.

South Korea added 4,388 new COVID-19 cases as of midnight Tuesday, for a total of 674,868 cases and 6,166 deaths since the pandemic began, the Korea Disease Control and Prevention Agency (KDCA) reported.

That number has dipped from all-time highs of nearly 8,000 daily cases in mid-December, when authorities re-imposed strict social distancing measures to try to stem the tide.

Omicron only accounts for a fraction of South Korea's cases so far, but that percentage has risen to more than 12.5% from 4% at the end of December, health officials said on Wednesday.

(Reporting by Heekyong Yang, Joyce Lee, and Yeni Seo; Writing by Josh Smith; Editing by Clarence Fernandez)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. -1.23% 130.58 Delayed Quote.-48.00%
ON SEMICONDUCTOR CORPORATION 2.94% 56.155 Delayed Quote.-19.76%
TAKEDA PHARMACEUTICAL COMPANY LIMITED -0.26% 3787 Delayed Quote.21.04%
Latest news "Economy & Forex"
04:09pU.S. Senate struggles to unite on guns after Texas massacre
RE
04:03pWorld Bank's Malpass says war in Ukraine may trigger global recession
RE
04:02pCommodities in 'perfect storm' says ERG, as crisis starts super cycle
RE
04:01pWall Street climbs after Fed minutes meet expectations
RE
03:58pGlobal shares rise after Fed meeting notes hint at future rate hikes
RE
03:56pGlobal shares rise after Fed meeting notes hint at future rate hikes
RE
03:50pRussia offers fast-track citizenship to residents of occupied Ukraine
RE
03:49pELON MUSK : Twitter investors vote against re-electing Elon Musk ally to board
RE
03:48p30-Year Treasury Yield Falls to 2.965% -- Data Talk
DJ
03:48p10-Year Treasury Yield Falls to 2.746% -- Data Talk
DJ
Latest news "Economy & Forex"